The FDA O.K.'s Novartis' IlarisKerry Capell
On June 18 the U.S. Food & Drug Administration approved Ilaris, a biotech drug for a rare cluster of autoimmune diseases caused by a single genetic mutation. For its manufacturer, Novartis (NVS), the approval is vindication of the Swiss pharmaceutical firm's radical new approach to drug development.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.